Guardian Pharmacy Services financials
$40.68−0.15%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $1.45B | $1.23B |
| Gross profit | $292.7M | $244.4M |
| Gross margin | 20.2% | 19.9% |
| Operating income | $72.7M | -$62.9M |
| Net income | $49.2M | -$110.0M |
| Net margin | 3.4% | −9.0% |
| Diluted EPS | $0.78 | $-1.77 |
| EBITDA | $95.0M | -$43.1M |
| Operating cash flow | $100.3M | $58.0M |
| Free cash flow | $80.7M | $41.6M |
| Diluted shares | 63.3M | 62.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $65.6M | $4.7M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 |
| Total assets | $412.7M | $320.8M |
| Total liabilities | $194.7M | $170.8M |
| Shareholders' equity | $217.9M | $150.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology